Business Description
CARISMA Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US14216R1014
Description
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.54 | |||||
| Equity-to-Asset | 0.15 | |||||
| Debt-to-Equity | 0.69 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | -7.09 | |||||
| Beneish M-Score | 0.93 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -54.6 | |||||
| 3-Year EPS without NRI Growth Rate | -54.3 | |||||
| 3-Year FCF Growth Rate | -53.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 11.88 | |||||
| 9-Day RSI | 19.42 | |||||
| 14-Day RSI | 25.4 | |||||
| 6-1 Month Momentum % | -32.79 | |||||
| 12-1 Month Momentum % | -64.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.64 | |||||
| Quick Ratio | 4.64 | |||||
| Cash Ratio | 4.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.3 | |||||
| Shareholder Yield % | 35.48 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -565.71 | |||||
| Net Margin % | -538.81 | |||||
| FCF Margin % | -524.92 | |||||
| ROE % | -171.7 | |||||
| ROA % | -72.61 | |||||
| ROIC % | -496.38 | |||||
| ROC (Joel Greenblatt) % | -805.69 | |||||
| ROCE % | -89.23 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.92 | |||||
| PB Ratio | 5.57 | |||||
| Price-to-Tangible-Book | 5.14 | |||||
| EV-to-EBIT | -0.11 | |||||
| EV-to-EBITDA | -0.11 | |||||
| EV-to-Revenue | 0.6 | |||||
| EV-to-Forward-Revenue | 0.62 | |||||
| EV-to-FCF | -0.15 | |||||
| Earnings Yield (Greenblatt) % | -910.93 | |||||
| FCF Yield % | -136.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CARISMA Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 13.93 | ||
| EPS (TTM) (€) | -1.812 | ||
| Beta | 0 | ||
| Volatility % | 127.2 | ||
| 14-Day RSI | 25.4 | ||
| 14-Day ATR (€) | 0.060484 | ||
| 20-Day SMA (€) | 1.45125 | ||
| 12-1 Month Momentum % | -64.78 | ||
| 52-Week Range (€) | 1.233 - 8.25 | ||
| Shares Outstanding (Mil) | 41.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CARISMA Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CARISMA Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
CARISMA Therapeutics Inc Frequently Asked Questions
What is CARISMA Therapeutics Inc(STU:W2J)'s stock price today?
The current price of STU:W2J is €1.23. The 52 week high of STU:W2J is €8.25 and 52 week low is €1.23.
When is next earnings date of CARISMA Therapeutics Inc(STU:W2J)?
The next earnings date of CARISMA Therapeutics Inc(STU:W2J) is 2024-08-09 Est..
Does CARISMA Therapeutics Inc(STU:W2J) pay dividends? If so, how much?
CARISMA Therapeutics Inc(STU:W2J) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers